The distinction between desvenlafaxine ER and desvenlafaxine succinate ER lies in the salt form of the active pharmaceutical ingredient. Desvenlafaxine ER is a formulation of desvenlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI) used to treat major depressive disorder [1]. Desvenlafaxine succinate ER is a specific salt form of desvenlafaxine, where succinic acid is used to create the salt [2]. This salt form can affect properties such as solubility, stability, and bioavailability.
What is the active ingredient in desvenlafaxine succinate ER?
The active ingredient in desvenlafaxine succinate ER is desvenlafaxine [2]. Desvenlafaxine is the active metabolite of venlafaxine and works by increasing the levels of serotonin and norepinephrine in the brain [1].
How does the succinate salt form impact the drug?
The succinate salt form is chosen for various pharmaceutical reasons. Drug manufacturers may select a specific salt form to improve the drug's physical and chemical properties. For desvenlafaxine succinate ER, this could translate to enhanced stability or a more consistent absorption profile in the body compared to other potential salt forms [2].
When does the patent for desvenlafaxine expire?
Information on specific patent expiry dates for desvenlafaxine, including its succinate salt form, can be found through patent tracking resources. For example, DrugPatentWatch.com provides data on drug patents and their expiration timelines [3]. These dates are critical for understanding when generic versions of the medication may become available.
What are the generic alternatives for desvenlafaxine ER?
Once patents expire and regulatory hurdles are cleared, generic versions of desvenlafaxine ER can enter the market. These generics would offer the same active ingredient and therapeutic effect as the branded product, typically at a lower cost [1, 3].
Who manufactures desvenlafaxine succinate ER?
The original branded product containing desvenlafaxine succinate ER is Pristiq, manufactured by Pfizer [2]. Following patent expirations, other pharmaceutical companies may produce and market generic versions of desvenlafaxine succinate ER.
What is the typical dosage and administration for desvenlafaxine ER?
Desvenlafaxine ER is typically administered orally once daily [1]. The dosage is usually initiated at 50 mg per day, with the potential to increase to a maximum of 400 mg per day, depending on individual patient response and tolerance [1].
What are the common side effects of desvenlafaxine ER?
Common side effects associated with desvenlafaxine ER include nausea, dry mouth, dizziness, insomnia, somnolence, decreased appetite, sweating, and constipation [1].
Sources:
[1] https://www.drugpatentwatch.com/drugs/desvenlafaxine
[2] https://www.drugpatentwatch.com/drugs/desvenlafaxine-succinate-er
[3] https://www.drugpatentwatch.com